Somatuline Depot
Payments companies reported to CMS as associated with Somatuline Depot. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Somatuline Depot, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Somatuline Depot
These are the largest totals companies reported as associated with Somatuline Depot. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Paul Oberstein | New York, NY | Medical Oncology | $5,673.05 |
| Andrew Hendifar | West Hollywood, CA | Hematology & Oncology | $5,220.00 |
| Sreenivasa Chandana | Grand Rapids, MI | Hematology & Oncology | $4,803.75 |
| John Burke | Aurora, CO | Hematology & Oncology | $3,915.00 |
| Shubham Pant | Houston, TX | Hematology & Oncology | $3,915.00 |
| Aman Chauhan | San Francisco, CA | Medical Oncology | $3,578.35 |
| Maen Abdelrahim | Houston, TX | Medical Oncology | $3,509.65 |
| Andrew Zelenetz | New York, NY | Medical Oncology | $3,480.00 |
| Maria Fleseriu | Portland, OR | Endocrinology, Diabetes & Metabolism | $3,130.68 |
| Igor Puzanov | Buffalo, NY | Hematology & Oncology | $2,610.00 |
Prescribed Somatuline Depot?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.